Skip to content
RushPR News – Lifestyle
Author:
HUYABIO International
HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial
October 22, 2026
HUYABIO International Announces Pivotal Data for HBI-8000 in Advanced Melanoma Selected for Late-Breaking Presentation at ESMO Congress 2026
September 29, 2026
HUYABIO International Delivers Significant Landmark Phase 3 Results in Advanced Melanoma
July 14, 2026